¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"deficiency symptom"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • initial symptom
    ÃʱâÁõ»ó
  • keynote symptom
    ÁÖ¿äÁõ»ó
  • local symptom
    ±¹¼ÒÁõ»ó
  • mild symptom
    °æÁõ»ó, °¡º­¿îÁõ»ó
  • negative symptom
    À½¼ºÁõ»ó
  • objective symptom
    Ÿ°¢Áõ»ó
  • pathognomonic symptom
    Áúº´Æ¯À¯Áõ»ó
  • positive symptom
    ¾ç¼ºÁõ»ó
  • postictal symptom
    ¹ßÀÛÈÄÁõ»ó
  • premonitory symptom
    (¢¡signal symptom) °æ°íÁõ»ó
  • presenting symptom
    ÇöÀçÁõ»ó
  • primary symptom
    ÀÏÂ÷Áõ»ó
  • prodromal symptom
    Àü±¸Áõ»ó
  • symptom
    Áõ»ó
  • signal symptom
    °æ°íÁõ»ó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • apolipoprotein C-Il deficiency
    ¾ÆÆ÷Áö´Ü¹é C-II °áÇÌ
  • apolipoprotein b, deficiency
    ¾ÆÆ÷¸®Æ÷´Ü¹éB°áÇÌÁõ(¡­Ó±ÛÜ¡­ÌÀù¹ñø)
  • arylsulfatase a deficiency
    ¾Æ¸±¼³ÆÄŸÁ¦ A °áÇÌÁõ(¡­ÌÀù¹ñø)
  • aspartylglycosamine amide hydrolase, deficiency
    Aspartylglycosamine amide hydrolase°áÇÌ(¡­ÌÀù¹)
  • functional deficiency
    ±â´É°áÇÌ
  • g6pd deficiency
    G6PD(Æ÷µµ´ç-6-Àλ꿰 Å»¼ö¼ÒÈ¿¼Ò) °áÇÌÁõ
  • galactosidase, alpha-galactosidase a, deficiency
    #NAME?
  • glucocerebrosidase deficiency
    ±Û·çÄÚ¼¼·¹ºê·Î½Ãµ¥À̽º °áÇÌÁõ
  • glucose 6 phosphatase deficiency hepa
    ±Û·çÄÚ¿À½º-6 -ÀÎ»ê °áÇ̰£½ÅÇü´ç
  • glucose-6-phosphate dehydrogenase deficiency
    ±Û·çÄÚ½º-6-ÀλêµðÇÏÀÌ µå·ÎÀú³×À̽º °áÇÌ(Áõ)
  • glucuronidase deficiency disease
    ±Û·çÅ¥·Î´Ïµ¥À̽º °áÇÌÁõ
  • glutathione reductase deficiency
    ±Û·çŸƼ¿Â ȯ¿øÈ¿¼Ò °áÇÌÁõ.
  • glycosidase deficiency
    ±Û¸®ÄڽôپÆÁ¦°áÇÌ(Áõ).
  • gonadal deficiency
    »ý½Ä¼±ºÎÀü(ßæãÖàÍÝÕîï).
  • gonadal deficiency
    »ý½Ä¼±ºÎÀü(ßæãÖàÍÝÕîï).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • presenting symptom
    ÁÖÁõ»ó(ñ«ñøßÒ).
  • pressure symptom
    ¾Ð¹ÚÁõ»ó(äâÚÞñøßÒ).
  • pressure symptom
    ¾Ð¹ÚÁõ»ó(äâÚÞñøßÒ)
  • primary symptom
    ÀÏÂ÷¼º¡¡Áõ»ó
  • prodromal symptom
    Àü±¸Áõ»ó(îñÏÌñøßÒ).
  • prodromal symptom
    Àü±¸Áõ»ó£®
  • rainbow symptom
    È«·ûÁõ»ó(ûöëÌñøßÒ).
  • signal symptom
    °æ°íÁõ»ó(ÌíͱñøßÒ)
  • subjective symptom
    ÀÚ°¢Áõ»ó(¡­ñøßÒ).
  • subjective symptom
    ÀÚ°¢Áõ»ó(¡­ñøßÒ)
  • symptom
    Áõ»ó(ñøßÒ).
  • symptom
    Áõ»ó(ñøßÒ)
  • symptom
    Áõ»ó(ñøßÒ)
  • symptom checklist-90-revised(SCL-90-R)
    °£ÀÌÁ¤½ÅÁø´Ü°Ë»ç(SCL-90-R)
  • symptom clusters
    Áõ»ó±º(ñøßÉÏØ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
SCL-90 symptom checklist 90
SCL-90-R symptom checklist 90, revised
SDCL symptom distress check list
SF Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f...
SIQ Symptom Interpretation Questionnaire
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
SCL-90 Symptom Check List
SCL-90-R Symptom Check List
SCL-90 Symptom Check List 90
SCL-90-R Symptom Check List 90-R
SDS Symptom Distress Scale
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Anton's symptom
    ¾ÈÅæ Áõ»ó
    º¸Åë ÀÎÁöÇÏÁö ¸øÇÏ´Â °ÍÀ¸·Î ¸»À» Áö¾î³»¾î ÀÚ±â ÀÚ½ÅÀÇ ¸ÍÁ¡À» ºÎÁ¤ÇÑ´Ù. Èĵο±ÀÇ ¾çÃø¼º °æ»ö¿¡ ÀÇÇÑ ÇÇÁú¸ÍÀÇ °æ¿ì¿¡ º¼ ¼ö ÀÖ´Ù.
  • associated symptom
    °ü·Ã Áõ»ó
  • auditory symptom
    û°¢ Áõ»ó
  • autonomic symptom
    ÀÚÀ² ½Å°æ Áõ»ó, ÀÚÀ² ½Å°æ¼º Áõ»ó
  • Burghart's symptom
    ºÎ¸£°¡¸£Æ® Áõ»ó
    ÆóÀÇ ÀúÀü¹æ¿¡¼­ ³ª´Â ¼öÆ÷À½. Æó°áÇÙÀÇ Ãʱâ Áõ»óÀÇ Çϳª.
  • cardinal symptom
    ÁÖ¿ä Áõ»ó, ÁÖÁõ
    1. Áø´Ü»ó Àǻ翡°Ô °¡Àå Áß¿äÇÑ Áõ»ó. 2. ¸Æ¹Ú, ü¿Â, È£Èí µî.
  • Castellani-Low symptom
    Ä«½ºÅÚ¶ó´Ï-·Î¿ì Áõ»ó
    ¼ö¸éº´ ȯÀÚ¿¡°Ô¼­ º¼ ¼ö ÀÖ´Â ¼³ ÁøÀü.
  • characteristic symptom
    Ư¼º Áõ»ó
  • chronic factitious disorder with physical symptom
    ¸¸¼º ÀΰøÀû Àå¾Ö ½ÅüÀû
  • conocomitant symptom
    ¼ö¹Ý Áõ»ó
    ÁÖ¿ä Áõ»óÀº ¾Æ´Ï³ª Áø´Ü¿¡´Â µµ¿òÀÌ µÇ´Â Áõ»ó.
  • constitutional symptom
    Àü½Å Áõ»ó, üÁú Áõ»ó
    Àü½ÅÀÇ Àå¾Ö¸¦ ½Ã»çÇϴ ȤÀº Àü½ÅÀÇ Àå¾Ö¿¡ ÀÇÇÑ Áõ»ó.
  • crossbar symptom of Fraenkel
    ÇÁ·»ÄÌ ºøÀå Áõ»ó
    X-¼± Åõ»ç ½Ã¿¡ À§¼Ò¸¸ÀÇ ±Ë¾ç ºÎ±Ù¿¡¼­ ¿¬µ¿ÆÄÀÇ ¼Ò½ÇÀÌ ³ªÅ¸³ª´Â °Í.
  • cutaneous symptom
    ÇǺΠÁõ»ó
  • delayed symptom
    Áö¿¬ Áõ»ó
    ±× Áúº´À» ÀÏÀ¸Å°´Â ¿øÀÎÀÌ ÀÖÀº ÈÄ¿¡ ÀÏÁ¤ ±â°£µ¿¾ÈÀº ³ªÅ¸³ªÁö ¾Ê¾Ò´Ù°¡ ÃßÈÄ¿¡ ³ªÅ¸³ª´Â °Í.
  • dissociation symptom
    ÇØ¸® Áõ»ó
    Ã˰¢Àº Á¤»óÀ̳ª Åë°¢, ¿Âµµ °¨°¢Àº ¼Ò½ÇµÇ´Â °Í. ô¼ö °øµ¿Áõ¿¡¼­ º¼ ¼ö ÀÖ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
abdominal muscle deficiency syndrome <syndrome> Congenital absence (partial or complete) of abdominal muscles, in which the outline of the intestines is visible through the protruding abdominal wall; in males, genitourinary anomalies (urinary tract dilation and cryptorchidism) are also found; genetics unclear.
(05 Mar 2000)
adult lactase deficiency Onset of lactase deficiency, with resulting milk intolerance and malabsorption, in adulthood. Inherited forms may not be manifested until adulthood; any process that damages the intestinal lining cells can cause lactase deficiency in adults.
(05 Mar 2000)
alpha-1 antitrypsin deficiency <chest medicine> Deficiency of the protease inhibitor alpha-1 antitrypsin, leads primarily to degradation of elastin of the alveolar walls, as well as other structural proteins of a variety of tissues.
The lack of this protein leads to damage of various organs, but mainly to the lung and liver.
symptoms may become apparent at a very early age or in adulthood, manifesting either as shortness of breath or liver related symptoms (jaundice, fatigue, fluid in the abdomen, mental changes, or gastrointestinal bleeding). There are several options for treatment of the lung disease, including replacement of the missing protein. Treatment of the liver disease is a well-timed liver transplant
(12 Dec 1998)
alpha-1-proteinase deficiency Absence of a serum proteinase inhibitor that may cause nodular non-suppurative panniculitis.
(05 Mar 2000)
alpha-antitrypsin deficiency <enzyme> A specific enzyme (alpha 1 antitrypsinase) that when absent genetically can result in panacinar emphysema (lung disease) and liver disease.
There is no specific treatment for this condition other than supportive care for the liver and lung complications.
Medications such as alpha-1proteinase inhibitor is given regularly to these patients.
Incidence: approximately 1 in 10,000.
(02 Jan 1998)
anaemia, iron deficiency Deficiency of iron results in anaemia because iron is necessary to make haemoglobin, the key molecule in red blood cells responsible for the transport of oxygen. In iron deficiency anaemia, the red cells are unusally small (microcytic) and pale (hypochromic). Characteristic features of iron deficiency anaemia in children include failure to thrive (grow) and increased infections. The treatment of iron deficiency anaemia, whether it be in children or adults, is with iron and iron-containing foods. Food sources of iron include meat, poultry, eggs, vegetables and cereals (especially those fortified with iron). According to the National Academy of Sciences, the Recommended Dietary Allowances of iron are 15 milligrams per day for women and 10 milligrams per day for men.
Anaemia characterised by low or absent iron stores, low serum iron concentration, elevated free erythrocyte porphorin, low transferrin saturation, elevated transferrin, low serum ferritin, low haemoglobin concentration or haematocrit, and hypochromic microcytic red blood cells. Symptoms may include pallor, angular stomatitis and other oral lesions, gastrointestinal complaints, retinal haemorrhages and exudates, and thinning and brittleness of the nails. Among the causes of iron-deficiency anaemia are inadequate iron intake, impaired iron absorption, increased blood loss and increased requirements such as infancy, pregnancy, and lactation.
(12 Dec 1998)
antibody deficiency disease <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms.
See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency.
Synonym: antibody deficiency disease.
(05 Mar 2000)
antibody deficiency syndrome <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms.
See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency.
Synonym: antibody deficiency disease.
(05 Mar 2000)
antitrypsin deficiency Deficiency of a1-antitrypsin, a glycoprotein of the postalbumin region of human serum. Many forms are known which may be moderate (40 to 60% of normal activity) or severe (less than 10% of normal), all autosomal dominant; the severe form is often associated with familial emphysema or hepatic cirrhosis.
(05 Mar 2000)
arch length deficiency The difference between the available circumference of the dental arch and that required to accommodate the succedaneous teeth in proper alignment.
(05 Mar 2000)
arginase deficiency <biochemistry> Arginase is the fifth enzyme of the urea cycle and catalyses the hydrolysis of arginine to ornithine and urea as the final step in the detoxification of ammonia.
Deficiency of the enzyme results in hyperargininaemia and episodic hyperammonaemia, leading to moderate to severe mental retardation and spasticity. at least two isozymes of arginase exist in man. AI (the enzyme deficient in the disorder) is cytosolic and found primarily in liver and red blood cells, whereas AII is mitochondrial and found predominantly in kidney but also to a lesser extent in liver, brain, and other tissues.
While AII activity appears to be induced in AI deficiency, it is only partially effective in maintaining urea cycle function. The normal in vivo function of AII is unclear.
Arginase deficiency is diagnosed by observing high arginine concentrations on either qualitative or quantitative plasma or urine amino acid analysis. The diagnosis is confirmed by finding markedly decreased or absent arginase activity in an isotopic red blood cell enzymatic assay. The AI gene has been cloned, sequenced, and localised to human chromosome band 6q23.
(17 Dec 1997)
ascorbic acid deficiency A condition due to a dietary deficiency of ascorbic acid (vitamin c), characterised by malaise, lethargy, and weakness. As the disease progresses, joints, muscles, and subcutaneous tissues may become the sites of haemorrhage. Ascorbic acid deficiency frequently develops into scurvy in young children fed unsupplemented cow's milk exclusively during their first year. It develops also commonly in chronic alcoholism. (cecil textbook of medicine, 19th ed, p1177)
(12 Dec 1998)
beta-d-glucuronidase deficiency A rare deficiency of beta-d-glucuronidase; an autosomal recessive disorder with several allelic forms, characterised by abnormal mucopolysaccharide metabolism leading to progressive mental deterioration, splenic and hepatic enlargement, and dysostosis multiplex.
Synonym: mucopolysaccharidase.
(05 Mar 2000)
brancher deficiency glycogenosis Type of glycogen storage disease, due to deficiency of amylo-1,4-1,6-transglucosidase (brancher enzyme).
Synonym: brancher deficiency glycogenosis, debrancher deficiency.
(05 Mar 2000)
calcium deficiency A low blood calcium (hypocalcaemia) makes the nervous system highly irritable with tetany (spasms of the hands and feet, muscle cramps, abdominal cramps, overly active reflexes, etc.). Chronic calcium deficiency contributes to poor mineralization of bones, soft bones (osteomalacia) and osteoporosis; and, in children, rickets and impaired growth. Food sources of calcium include dairy foods, some leafy green vegetables such as broccoli and collards, canned salmon, clams, oysters, calcium-fortified foods, and tofu. According to the National Academy of Sciences, adequate intake of calcium is 1 gram daily for both men and women. The upper limit for calcium intake is 2.5 grams daily.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á